| All treatments | LNZ daily dose ≤600 mg | LNZ daily dose >600 mg | p-value | |
| Patients treated with linezolid | 72 (59.5) | 49 (40.5) | ||
| XDR-TB | 25/71 (35.2) | 14/49 (28.6) | 0.45 | |
| Sputum smear conversion | 86/93 (92.5) | 54/59 (91.5) | 42/44 (95.5) | 0.43 |
| Culture conversion | 100/107 (93.5) | 54/59 (91.5) | 46/48 (95.8) | 0.37 |
| Period from start of anti-TB therapy to sputum smear conversion days | 43.5 (21–90) | 45.5 (28–91) | 92.5 (35–120) | 0.02 |
| 2-month culture conversion | 37/72 (51.4) | 18/42 (42.9) | 19/30 (63.3) | 0.09 |
| Period from start of anti-TB therapy to culture conversion days | 61 (29–119) | 28 (20–45) | 60 (42–115) | 0.07 |
| Definite treatment outcomes | ||||
| Cured | 98/121 (81.0) | 59/72 (81.9) | 39/49 (79.6) | 0.75 |
| Treatment completed | 1/121 (0.8) | 1/72 (1.4) | ||
| Died | 17/121 (14.1) | 9/72 (12.5) | 8/49 (16.3) | 0.56 |
| Failed | 5/121 (4.1) | 3/72 (4.2) | 2/49 (4.1) | 0.98 |
Data are presented as n (%), n/N (%) or median (interquartile range), unless otherwise stated. LNZ: linezolid; XDR-TB: extensively drug-resistant TB.